News

Adnectins are designed by using BMS‘ proprietary PROfusion technology to either block or stimulate the action of specific targets across a range of therapeutic areas. Under the agreement,

The active ingredient in BSCT topical treatment is a polyclonal antibody directed towards Biosceptre’s novel proprietary cancer target, nf-P2X7. Biosceptre expects to start clinical studies for BSCT at

XF-73, a novel dicationic porphyrin, is under development for the prevention of post-surgical Staphylococcal infections. The Phase 1 trial aims to evaluate the safety, tolerability and preliminary anti-Staphylococcal

Intercell has posted a net loss of EUR1.61m for the second quarter of 2011, compared to EUR8.35m for the same period in 2010. The company’s operating loss was

The advanced center houses the latest technologies for mixing, compounding, molding and finishing elastomer packaging components. West Marketing and Strategic Business Development vice president Fran DeGrazio said the

The trial evaluating Natroba demonstrated efficacy against permethrin 1% without nit combing. In Phase III clinical studies, Natroba was shown to be more effective at eliminating head lice

The primary endpoint of the trial was the percentage of ‘off time’ during waking hours as measured by patient diary. ‘Off time’ is the functional state when patients’

The increase in sales was primarily due to the increase in company’s main product Xuesaitong in Tianjin City and Yunnan Province and enhanced sales promotion in Yunnan Province.

The study aims to investigate the pharmacokinetics (PK) and safety profile of UX001 in around 24 patients. The study expects to test four different single-dose levels in each